| Product Code: ETC9976147 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Short Bowel Syndrome Drugs Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Short Bowel Syndrome Drugs Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Short Bowel Syndrome Drugs Market - Industry Life Cycle |
3.4 United States (US) Short Bowel Syndrome Drugs Market - Porter's Five Forces |
3.5 United States (US) Short Bowel Syndrome Drugs Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 United States (US) Short Bowel Syndrome Drugs Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.7 United States (US) Short Bowel Syndrome Drugs Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.8 United States (US) Short Bowel Syndrome Drugs Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 United States (US) Short Bowel Syndrome Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of short bowel syndrome in the United States |
4.2.2 Technological advancements in drug development for treating short bowel syndrome |
4.2.3 Growing healthcare expenditure and favorable reimbursement policies for expensive drugs |
4.3 Market Restraints |
4.3.1 High cost associated with short bowel syndrome drugs |
4.3.2 Stringent regulations for drug approval and market entry |
4.3.3 Limited awareness among healthcare professionals and patients about short bowel syndrome and its treatment options |
5 United States (US) Short Bowel Syndrome Drugs Market Trends |
6 United States (US) Short Bowel Syndrome Drugs Market, By Types |
6.1 United States (US) Short Bowel Syndrome Drugs Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Short Bowel Syndrome Drugs Market Revenues & Volume, By Drug Class, 2021- 2031F |
6.1.3 United States (US) Short Bowel Syndrome Drugs Market Revenues & Volume, By Glucagon-like Peptide, 2021- 2031F |
6.1.4 United States (US) Short Bowel Syndrome Drugs Market Revenues & Volume, By Anti-Diarrheal, 2021- 2031F |
6.1.5 United States (US) Short Bowel Syndrome Drugs Market Revenues & Volume, By Histamine Blockers, 2021- 2031F |
6.1.6 United States (US) Short Bowel Syndrome Drugs Market Revenues & Volume, By Proton Pump Inhibitors, 2021- 2031F |
6.1.7 United States (US) Short Bowel Syndrome Drugs Market Revenues & Volume, By Growth Hormone, 2021- 2031F |
6.1.8 United States (US) Short Bowel Syndrome Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.2 United States (US) Short Bowel Syndrome Drugs Market, By Route of Administration |
6.2.1 Overview and Analysis |
6.2.2 United States (US) Short Bowel Syndrome Drugs Market Revenues & Volume, By Oral, 2021- 2031F |
6.2.3 United States (US) Short Bowel Syndrome Drugs Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.2.4 United States (US) Short Bowel Syndrome Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.3 United States (US) Short Bowel Syndrome Drugs Market, By End-Users |
6.3.1 Overview and Analysis |
6.3.2 United States (US) Short Bowel Syndrome Drugs Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.3.3 United States (US) Short Bowel Syndrome Drugs Market Revenues & Volume, By Homecare, 2021- 2031F |
6.3.4 United States (US) Short Bowel Syndrome Drugs Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.3.5 United States (US) Short Bowel Syndrome Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.4 United States (US) Short Bowel Syndrome Drugs Market, By Distribution Channel |
6.4.1 Overview and Analysis |
6.4.2 United States (US) Short Bowel Syndrome Drugs Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.4.3 United States (US) Short Bowel Syndrome Drugs Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.4.4 United States (US) Short Bowel Syndrome Drugs Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
7 United States (US) Short Bowel Syndrome Drugs Market Import-Export Trade Statistics |
7.1 United States (US) Short Bowel Syndrome Drugs Market Export to Major Countries |
7.2 United States (US) Short Bowel Syndrome Drugs Market Imports from Major Countries |
8 United States (US) Short Bowel Syndrome Drugs Market Key Performance Indicators |
8.1 Patient adherence rate to prescribed short bowel syndrome drugs |
8.2 Number of clinical trials for new drug development in the short bowel syndrome market |
8.3 Percentage of healthcare providers trained in diagnosing and managing short bowel syndrome |
9 United States (US) Short Bowel Syndrome Drugs Market - Opportunity Assessment |
9.1 United States (US) Short Bowel Syndrome Drugs Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 United States (US) Short Bowel Syndrome Drugs Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.3 United States (US) Short Bowel Syndrome Drugs Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.4 United States (US) Short Bowel Syndrome Drugs Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 United States (US) Short Bowel Syndrome Drugs Market - Competitive Landscape |
10.1 United States (US) Short Bowel Syndrome Drugs Market Revenue Share, By Companies, 2024 |
10.2 United States (US) Short Bowel Syndrome Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here